{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:54:16Z","timestamp":1784638456754,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ijidonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ijid.2019.01.013","type":"journal-article","created":{"date-parts":[[2019,1,12]],"date-time":"2019-01-12T00:04:39Z","timestamp":1547251479000},"page":"S74-S79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"S","title":["Bioethics of establishing a CHIM model for dengue vaccine development"],"prefix":"10.1016","volume":"84","author":[{"given":"Anuradha","family":"Rose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Sekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijid.2019.01.013_bib0005","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/infdis\/jit436","article-title":"A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand","volume":"209","author":"Anderson","year":"2014","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.ijid.2019.01.013_bib0010","doi-asserted-by":"crossref","first-page":"456","DOI":"10.11622\/smedj.2014114","article-title":"The potential for a controlled human infection platform in Singapore","volume":"55","author":"Balasingam","year":"2014","journal-title":"Singapore Med J"},{"issue":"1","key":"10.1016\/j.ijid.2019.01.013_bib0015","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/phe\/phv026","article-title":"Ethical criteria for human challenge studies in infectious diseases","volume":"9","author":"Bambery","year":"2016","journal-title":"Public Health Ethics"},{"issue":"9951","key":"10.1016\/j.ijid.2019.01.013_bib0020","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.ijid.2019.01.013_bib0025","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1093\/infdis\/jiu061","article-title":"Dengue human infection model: introduction","volume":"209","author":"Cassetti","year":"2014","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.ijid.2019.01.013_bib0030","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1473-3099(15)00068-7","article-title":"Design, recruitment, and microbiological considerations in human challenge studies","volume":"15","author":"Darton","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2019.01.013_bib0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.12688\/wellcomeopenres.12256.1","article-title":"A framework for Controlled Human Infection Model (CHIM) studies in Malawi: report of a Wellcome Trust workshop on CHIM in Low Income Countries held in Blantyre, Malawi","volume":"2","author":"Gordon","year":"2017","journal-title":"Wellcome Open Res"},{"issue":"50","key":"10.1016\/j.ijid.2019.01.013_bib0040","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1016\/j.vaccine.2015.09.108","article-title":"Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward","volume":"33","author":"Guy","year":"2015","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.ijid.2019.01.013_bib0045","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and long-term safety of a dengue vaccine in regions of endemic disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2019.01.013_bib0050","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12936-015-0671-x","article-title":"Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, Kenya","volume":"14","author":"Hodgson","year":"2015","journal-title":"Malar J"},{"issue":"7361","key":"10.1016\/j.ijid.2019.01.013_bib0055","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nature10356","article-title":"Successful establishment of Wolbachia in Aedes populations to suppress dengue transmission","volume":"476","author":"Hoffmann","year":"2011","journal-title":"Nature"},{"issue":"6365","key":"10.1016\/j.ijid.2019.01.013_bib0060","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"issue":"330","key":"10.1016\/j.ijid.2019.01.013_bib0065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf1517","article-title":"The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model","volume":"8","author":"Kirkpatrick","year":"2016","journal-title":"Sci Transl Med"},{"issue":"50","key":"10.1016\/j.ijid.2019.01.013_bib0070","doi-asserted-by":"crossref","first-page":"7075","DOI":"10.1016\/j.vaccine.2015.09.052","article-title":"Dengue human infection models to advance dengue vaccine development","volume":"33","author":"Larsen","year":"2015","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.ijid.2019.01.013_bib0075","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1093\/infdis\/jiw423","article-title":"Current status of dengue therapeutics research and development","volume":"215","author":"Low","year":"2017","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.ijid.2019.01.013_bib0080","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S1473-3099(14)70730-3","article-title":"Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial","volume":"14","author":"Low","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.ijid.2019.01.013_bib0085","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/infdis\/jiu174","article-title":"The human dengue challenge experience at the Walter Reed Army Institute of Research","volume":"209","author":"Lyons","year":"2014","journal-title":"J Infect Dis"},{"issue":"13","key":"10.1016\/j.ijid.2019.01.013_bib0090","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.vaccine.2013.12.040","article-title":"Evaluation of dengue virus strains for human challenge studies","volume":"32","author":"Mammen","year":"2014","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.ijid.2019.01.013_bib0095","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/infdis\/jis470","article-title":"A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients","volume":"207","author":"Nguyen","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2019.01.013_bib0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/s13071-015-1174-x","article-title":"Field evaluation of the establishment potential of wMelPop Wolbachia in Australia and Vietnam for dengue control","volume":"8","author":"Nguyen","year":"2015","journal-title":"Parasites Vectors"},{"issue":"4","key":"10.1016\/j.ijid.2019.01.013_bib0105","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of dengue serostatus on dengue vaccine safety and efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ijid.2019.01.013_bib0110","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1473-3099(16)00026-8","article-title":"The global burden of dengue: an analysis from the Global Burden of Disease Study 2013","volume":"16","author":"Stanaway","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.ijid.2019.01.013_bib0115","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.cct.2010.12.003","article-title":"More than the money: a review of the literature examining healthy volunteer motivations","volume":"32","author":"Stunkel","year":"2011","journal-title":"Contemp Clin Trials"},{"issue":"5","key":"10.1016\/j.ijid.2019.01.013_bib0120","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/infdis\/jis744","article-title":"Experimental dengue virus challenge of human subjects previously vaccinated with live attenuated tetravalent dengue vaccines","volume":"207","author":"Sun","year":"2013","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.ijid.2019.01.013_bib0125","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/21645515.2016.1261770","article-title":"Vaccines licensed and in clinical trials for the prevention of dengue","volume":"13","author":"Torresi","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"24","key":"10.1016\/j.ijid.2019.01.013_bib0130","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1016\/j.vaccine.2018.02.062","article-title":"Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines","volume":"36","author":"Vannice","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ijid.2019.01.013_bib0135","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijid.2019.01.013_bib0140","series-title":"Meeting of the Strategic Advisory Group of Experts on immunization, April 2018\u2014conclusions and recommendations","first-page":"329","author":"WER","year":"2018"},{"issue":"1","key":"10.1016\/j.ijid.2019.01.013_bib0145","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/S1473-3099(18)30494-8","article-title":"Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine","volume":"19","author":"Wilder-Smith","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.ijid.2019.01.013_bib0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004156","article-title":"Dispersal of engineered male Aedes aegypti mosquitoes","volume":"9","author":"Winskill","year":"2015","journal-title":"PLoS Negl Trop Dis"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971219300244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971219300244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T10:33:45Z","timestamp":1565346825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971219300244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":30,"alternative-id":["S1201971219300244"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2019.01.013","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bioethics of establishing a CHIM model for dengue vaccine development","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2019.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}